Plant Name: Cytisus scoparius
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; ADRA2C; ADRA2A; TAAR1; | |
| NMUR2; | |
| PTPN1; PTPN2; ACP1; CDC25B; PTPRF; | |
| RECQL; ALPI; PLA2G1B; HSD11B1; AKR1B10; AKR1B1; ALOX15; POLB; | |
| GAA; ATP12A; ACHE; | |
| MAPK1; | |
| CA2; CA1; CA12; CA9; CA13; CA7; CA4; | |
| RORC; | |
| NR1H4; | |
| KDM4E; | |
| HIF1A; NFKB1; | |
| ABCC1; | |
| LMNA; RAB9A; NPC1; MAPT; PAX8; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ATP12A | Potassium-transporting ATPase alpha chain 2 | P54707 | CHEMBL2933 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.290E-12 | 1.405E-08 | CA1, CA12, CA13, CA2, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.846E-12 | 3.182E-08 | CA1, CA12, CA13, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.290E-08 | 9.783E-05 | AKR1B1, AKR1B10, CYP1A1, CYP1A2, CYP1B1, HSD11B1, NPC1, NR1H4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.161E-07 | 5.833E-04 | CA2, CA7, HIF1A, MAPK1, NPC1, NR1H4, PLA2G1B |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.148E-06 | 9.681E-04 | ALPI, CA1, CA12, CA13, CA2, CA4, CA7, CA9, NR1H4, PTPN1, RORC |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.220E-06 | 9.837E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 2.635E-06 | 1.912E-03 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 3.128E-06 | 1.963E-03 | AKR1B1, AKR1B10, ALOX15, CYP1A1, CYP1B1, HIF1A, NPC1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 3.155E-06 | 1.963E-03 | AKR1B1, ALOX15, CA2, CA9, CYP1B1, HIF1A, LMNA, MAPK1, MAPT, NFKB1, POLB, PTPN1, PTPRF, RECQL |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.334E-06 | 2.017E-03 | ABCC1, ADRA2A, ATP12A, CA2, CA4, CA9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.580E-06 | 4.084E-03 | ADRA2A, CA2, CA7, HIF1A, MAPK1, NPC1, NR1H4, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 9.120E-06 | 4.137E-03 | ALOX15, CYP1A1, CYP1A2, CYP1B1, HIF1A, NPC1, NR1H4, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.197E-05 | 5.110E-03 | ADRA2A, AKR1B1, CA2, CA9, CYP1A2, NFKB1, NPC1, PAX8, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.329E-05 | 5.532E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.450E-05 | 5.532E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.450E-05 | 5.532E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.450E-05 | 5.532E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.450E-05 | 5.532E-03 | GPBAR1, NR1H4 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.473E-05 | 5.532E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.764E-05 | 6.402E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.764E-05 | 6.402E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 2.869E-05 | 8.547E-03 | ABCC1, AKR1B1, CA9, CYP1A1, CYP1B1, MAPK1, NFKB1, NPC1, POLB |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 2.896E-05 | 8.547E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.896E-05 | 8.547E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.896E-05 | 8.547E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.896E-05 | 8.547E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.896E-05 | 8.547E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.029E-15 | 2.241E-11 | CA1, CA12, CA13, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.432E-15 | 3.526E-13 | CA12; CA1; CA2; CA4; CA7; CA9; CA13 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.221E-06 | 5.235E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.810E-05 | 6.924E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.910E-05 | 6.924E-04 | PTPN1; MAPK1; ACP1; PTPRF |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.868E-05 | 7.476E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.652E-05 | 1.568E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.253E-05 | 7.476E-04 | PLA2G1B; CYP1A2; ALOX15 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.609E-05 | 7.476E-04 | AKR1B10; GAA; AKR1B1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.234E-04 | 6.821E-03 | ABCC1; CYP1B1; MAPK1; NFKB1; CDC25B |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.084E-03 | 1.463E-02 | HSD11B1; AKR1B10; PLA2G1B; GAA; CYP1A2; ALOX15; CYP1A1; AKR1B1; ALPI |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.410E-03 | 1.703E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.156E-03 | 1.861E-02 | MAPK1; MAPT; NFKB1; CDC25B |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.658E-03 | 1.830E-02 | PTPN1; NFKB1; PTPRF |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.906E-03 | 2.218E-02 | NMUR2; ADRA2C; TAAR1; ADRA2A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.182E-03 | 1.861E-02 | ABCC1; MAPK1; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.376E-03 | 2.331E-02 | LMNA; MAPK1; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.309E-03 | 2.331E-02 | PTPN1; MAPK1; PTPRF |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 5.524E-03 | 3.482E-02 | MAPK1; ADRA2C; ADRA2A |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.767E-03 | 1.830E-02 | PAX8; MAPK1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.110E-03 | 1.463E-02 | CA2; CA4 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.181E-03 | 3.415E-02 | CYP1A1; CYP1B1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.686E-03 | 3.719E-02 | MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.025E-02 | 3.719E-02 | PAX8; MAPK1; HIF1A; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.690E-03 | 3.719E-02 | POLB; MAPK1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.385E-03 | 3.719E-02 | MAPK1; HIF1A |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.716E-03 | 2.188E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.150E-03 | 1.861E-02 | AKR1B10; AKR1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.148E-03 | 3.719E-02 | AKR1B10; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.686E-03 | 3.719E-02 | MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.868E-03 | 3.719E-02 | PLA2G1B; ALOX15 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 8.619E-03 | 3.719E-02 | RORC; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.877E-03 | 3.719E-02 | MAPK1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.275E-02 | 4.203E-02 | PLA2G1B; MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.877E-03 | 3.719E-02 | MAPK1; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.619E-03 | 3.719E-02 | CYP1A2; CYP1A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 9.137E-03 | 3.719E-02 | MAPK1; HIF1A |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 8.619E-03 | 3.719E-02 | MAPK1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.049E-02 | 3.719E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.077E-02 | 3.719E-02 | MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.077E-02 | 3.719E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.021E-02 | 3.719E-02 | CA2; NR1H4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.571E-02 | 4.952E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.077E-02 | 3.719E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.472E-02 | 4.744E-02 | MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.134E-02 | 3.826E-02 | MAPK1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.070E-02 | 3.719E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; ACHE; ACHE; ACHE; MAPT |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ADRA2C; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9; MAPK1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA1; CA9; MAPK1; NFKB1; ACHE; CDC25B |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; PLA2G1B |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |